Skip to main navigation Skip to search Skip to main content

MET exon 14 skipping mutation is a hepatocyte growth factor (HGF)-dependent oncogenic driver in vitro and in humanised HGF knock-in mice

  • Marie Fernandes
  • , Brynna Hoggard
  • , Philippe Jamme
  • , Sonia Paget
  • , Marie José Truong
  • , Valérie Grégoire
  • , Audrey Vinchent
  • , Clotilde Descarpentries
  • , Angela Morabito
  • , Justas Stanislovas
  • , Enoir Farage
  • , Jean Pascal Meneboo
  • , Shéhérazade Sebda
  • , Katia Bouchekioua-Bouzaghou
  • , Marie Nollet
  • , Sarah Humez
  • , Timothy Perera
  • , Paul Fromme
  • , Luca Grumolato
  • , Martin Figeac
  • Marie Christine Copin, David Tulasne, Alexis B. Cortot, Stéphanie Kermorgant, Zoulika Kherrouche

Research output: Contribution to journal › Article › peer-review

14 Scopus citations

Abstract

Exon skipping mutations of the MET receptor tyrosine kinase (METex14), increasingly reported in cancers, occur in 3–4% of non–small-cell lung cancer (NSCLC). Only 50% of patients have a beneficial response to treatment with MET-tyrosine kinase inhibitors (TKIs), underlying the need to understand the mechanism of METex14 oncogenicity and sensitivity to TKIs. Whether METex14 is a driver mutation and whether it requires hepatocyte growth factor (HGF) for its oncogenicity in a range of in vitro functions and in vivo has not been fully elucidated from previous preclinical models. Using CRISPR/Cas9, we developed a METex14/WT isogenic model in nontransformed human lung cells and report that the METex14 single alteration was sufficient to drive MET-dependent in vitro anchorage-independent survival and motility and in vivo tumorigenesis, sensitising tumours to MET-TKIs. However, we also show that human HGF (hHGF) is required, as demonstrated in vivo using a humanised HGF knock-in strain of mice and further detected in tumour cells of METex14 NSCLC patient samples. Our results also suggest that METex14 oncogenicity is not a consequence of an escape from degradation in our cell model. Thus, we developed a valuable model for preclinical studies and present results that have potential clinical implication.

Original languageEnglish
Pages (from-to)2257-2274
Number of pages18
JournalMolecular Oncology
Volume17
Issue number11
DOIs
StatePublished - Nov 2023
Externally publishedYes

Keywords

  • hepatocyte growth factor
  • lung cancer
  • preclinical models
  • targeted therapies
  • transcriptomic
  • tyrosine kinase receptor

Fingerprint

Dive into the research topics of 'MET exon 14 skipping mutation is a hepatocyte growth factor (HGF)-dependent oncogenic driver in vitro and in humanised HGF knock-in mice'. Together they form a unique fingerprint.

Cite this